Who
Leanne M. Zumwalt
Director
Company insider
Files Form 4 as: Director, Akebia Therapeutics; Group VP, Government Affairs, DaVita; Director, Advisory Board Co.
In numbers
- Trades disclosed
- 170
- Buys
- 0
- Sells
- 36
- Bought
- $0
- Sold
- $17.1M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 9 Mar 2006
- Last trade
- 17 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 22 Jun 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —35,700 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —53,600 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —53,600 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —35,700 at $0.00 | filing |
| 10 Jun 2025filed 11 Jun 2025 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —53,600 at $0.00 | filing |
| 10 Jun 2025filed 11 Jun 2025 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —35,700 at $0.00 | filing |
| 6 Jun 2024filed 10 Jun 2024 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 6 Jun 2024filed 10 Jun 2024 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 6 Jun 2023filed 8 Jun 2023 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 6 Jun 2023filed 8 Jun 2023 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 8 Jun 2022filed 9 Jun 2022 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,100 at $0.00 | filing |
| 8 Jun 2022filed 9 Jun 2022 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —13,700 at $0.00 | filing |
| 16 Feb 2021filed 18 Feb 2021 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —80,200 at $0.00 | filing |
| 18 Sep 2020filed 22 Sep 2020 | DVA DaVitaoption or derivative · Providers & Facilities | SEC FORM 4 Code M | —26,459 at $0.00 | filing |
| 18 Sep 2020filed 22 Sep 2020 | DVA DaVitaoption or derivative · Providers & Facilities | SEC FORM 4 Code M | —10,456 at $0.00 | filing |
| 18 Sep 2020filed 22 Sep 2020 | DVA DaVitaProviders & Facilities | SEC FORM 4 Code M | $2.0M26,459 at $75.42 | filing |
| 18 Sep 2020filed 22 Sep 2020 | DVA DaVitaProviders & Facilities | SEC FORM 4 Code F | $2.2M24,190 at $90.14 | filing |
| 18 Sep 2020filed 22 Sep 2020 | DVA DaVitaProviders & Facilities | SEC FORM 4 Code M | $685K10,464 at $65.48 | filing |
| 18 Sep 2020filed 22 Sep 2020 | DVA DaVitaProviders & Facilities | SEC FORM 4 Code F | $808K8,961 at $90.14 | filing |
| 18 Sep 2020filed 22 Sep 2020 | DVA DaVitaProviders & Facilities | SEC FORM 4 Sold | $214K2,435 at $87.73 | filing |
News
DaVita Ransomware Settlement Opens Claims Under $15 Million CapDVA · econotimes.com · 21 Oct 20267,152 Shares of DaVita Inc. $DVA Purchased by Westwind CapitalDVA · dailypolitical.com · 9 Oct 2026
0 headlines in the last 90 days name Leanne M. Zumwalt; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.